3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
| Status: | Recruiting |
|---|---|
| Conditions: | Other Indications, Neurology |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/17/2018 |
| Start Date: | June 2001 |
| End Date: | June 2020 |
| Contact: | Erin E Clark |
| Email: | Erin.Clark@lahey.org |
| Phone: | 781-744-2862 |
Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS)
The purpose of this study is to determine the effectiveness and adverse effects of
3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and
Congenital Myasthenic Syndromes (CMS).
3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and
Congenital Myasthenic Syndromes (CMS).
Inclusion Criteria:
- LEMS diagnosis OR Pre or Post Synaptic CMS diagnosis
- 18 years or older
- Females must have negative pregnancy test and be willing to practice an effective form
of birth control
- No prolonged QT syndrome as indicated by baseline EKG
Exclusion Criteria:
- Known sensitivity to 3,4-DIAMINOPYRIDINE
- History of seizures and/or severe asthma
We found this trial at
1
site
Click here to add this to my saved trials
